Are we good? All right, welcome to this fireside chat with ADC Therapeutics. It is my great pleasure to welcome Ameet Mallik, CEO. Ameet, welcome. Thanks for joining us.
Yeah, thank you, Michael. Appreciate it.
So we will do the lightning round version here. This has been a year of contrast, I guess, for ADC Therapeutics. You had the LOTIS-5 readout, FDA feedback, and now you have a very impressive LOTIS-7 data coming up at ASH. Maybe talk about how you think ADC Therapeutics is positioned as we enter 2027.
Yeah, first of all, we have a commercial product. As a monotherapy, ZYNLONTA plays a meaningful role in the third-line plus DLBCL setting. As you mentioned, we have two really good data sets right now. We have the LOTIS-7 data looking at the combination of ZYNLONTA plus glofitamab in the second-line plus DLBCL setting. We also have ZYNLONTA monotherapy in marginal zone lymphoma. We think both of these data sets could be practice-changing, and we are pursuing a regulatory and compendia pathway for both of these. Given the recent PIPE and financial restructuring that we announced, we think we are in a very strong position to execute the strategy, and we think we have a good plan going forward. Okay.
Why don't we start talking about maybe starting with the near-term updates coming up at ASH. You obviously have, I think it's five orals in total, including the final LOTIS-7 data. Yeah, maybe talk about how important that LOTIS-7 data is and what will the ASH presentation essentially tell us beyond what we've seen in the abstract?
Yeah, so you probably saw the abstract data, obviously, and so we're very impressed that in the 97 efficacy-evaluable patients looking at ZYNLONTA plus glofitamab in second-line plus DLBCL, we showed an 89% overall response rate and 75% complete response rate. Importantly, the duration of those responses was also good. The duration of CR at one year was 79%. Just by way of comparison, when you look at other bispecific combos, the CR rates are typically between 51% and 61%. The duration of CRs are typically at one year between 63% and 75%. So we think this data looks really good right now. So that's obviously one of the key presentations. We plan to have an enhanced data presentation at the presentation at ASH, including potentially updated data as well.
Okay. Then, yeah, how do you think about the development opportunity for LOTIS-7 longer term? So, how does this combination fit into the DLBCL landscape right now, and then how could you pursue that formally, I suppose?
Yeah, so I think there's a lot of unmet need in the second-line plus setting. So outside of CAR-T, which is a clear standard of care, only about 20% of patients are getting a CAR-T in that second-line plus setting. Outside of that, the only targeted regimen that's approved today in second line is loncastuximab and lenalidomide. So there's very few options for patients right now in that second-line setting.
Obviously, there could be some more approvals that come about, but nonetheless, if you don't get a CAR-T, there's really not a lot of great therapeutic options. We think the glofitamab plus ZYNLONTA combination can play a meaningful role in that second-line plus setting. We have a Type B meeting planned with the FDA this quarter to talk about the phase III design, looking at ZYNLONTA plus glofitamab versus what we want to have as a much more active comparator arm, and a lot of the details we will disclose once we have had that meeting with the FDA.
Okay. The data looks particularly strong in primary refractory patients and also in the post-CAR-T setting. In addition to the broad second-line registration study, which you might be planning, are there other opportunities, if we think about some of these subgroups, where the combination could be particularly useful, perhaps, again, there is an accelerated path to market potentially in those?
Yeah, so I think, to your point, we are seeing a great response overall with a 75% complete response rate. Relapsed patients are close to 90%, and we are seeing more than a 60% complete response rate in both the primary refractory and the post-CAR-T population. Those are two of the highest unmet need populations that there are. So we are excited that in these very tough-to-treat populations, that we are seeing such compelling data. I think it is an area physicians are really excited about because there is not a lot of good options that work in those settings. Our plan right now from a regulatory standpoint is to go for a broad second-line plus population, but we will look at different options potentially for accelerated approval as well.
Okay, great. How does the safety profile compare to other therapies in this space?
Overall, we think it looks good. I mean, the AEs that we see, the AE profiles, really consistent with the known profiles of both agents, glofitamab and ZYNLONTA. What we're seeing right now from a CRS and ICANS standpoint looks quite good. We had just over a 30% CRS rate, low grades of ICANS, and everything we saw was grade 1 or 2, with the exception of one case of grade 3 CRS.
We think the fact that we're dosing ZYNLONTA ahead of the step-up dosing of glofitamab is helping to de-bulk the tumor and really reduce the rates and grades of CRS and ICANS, and we're seeing that play out now in about 100 patients. If you look at the grade 5 TEAEs, it's about 3%. Again, by way of comparison, when you look at just bispecific combo trials overall, that range is typically between 5% and 13%. We feel we're in a good place there. We think that the fact that we have infection prophylaxis in the protocol helps to really manage a lot of those AEs.
Right. Compendia listing was always one part of your plan and inclusion in NCCN guidelines. How quickly could the data be published and then be included in guidelines?
Yeah, so we plan to be able to publish the data around the time of the ASH presentation, ideally concomitantly with the ASH presentation. We expect that, typically when you look at NCCN guidelines and other compendia, they typically make those decisions in the first quarter of the following year. So we expect that that's when that would happen for us as well.
Okay. Maybe just circling back to LOTIS-5, you will also have the full presentation at ASH in its entirety. Based on your FDA discussions around the LOTIS-5 BLA, what is the next step here, and how do you think with the regulatory path for that particular study?
Yeah, so importantly, LOTIS-5 met the primary endpoint, but there was an imbalance in the grade 5 events. The FDA raised concerns around the benefit-risk profile, given the imbalance in AEs and the more marginal treatment difference between the two arms. We think the regulatory pathway is going to be more challenging. Part of what we will talk about with the FDA when we meet with them on the potential glofitamab-ZYNLONTA combination is potentially using that as the confirmatory study. We are still in discussions with the FDA. We think, nonetheless, LOTIS-5 can still play a role for patients because, as I said, there is not a lot of options. We do plan to not only share the data in an oral presentation, there will be more data.
For exam ple, looking at what was the grade 5 TEAEs for those patients who were prophylaxed versus not prophylaxed. I can tell you it was a meaningful difference in that. We will actually be providing more enriched data that has not been released up to this point. I think that will start to contextualize some of the data. Then we do plan to, again, publish it and submit that to NCCN as well.
Do you still plan to resubmit or submit this to the FDA, or will you step back now and focus on LOTIS-7?
We're in discussions. We are committed to making sure we have a confirmatory pathway for ZYNLONTA. A lot will depend on how these next discussions go with the FDA this quarter.
Okay, great. MZL, you just mentioned, is another focus opportunity. Maybe talk about some of the data that's been generated here and what sort of a more formal regulatory pathway could look like for MZL.
Yeah, so marginal zone lymphoma is an indolent disease, about 3,000 to 4,000 relapsed refractory patients in marginal zone lymphoma in the U.S. It really is dominated mainly by BTK inhibitors. That's what really most patients are getting. When you look at the CR rates for the majority of the therapies, especially outside of CAR-T, really they're sub 30% CR rates. What we saw in our study is a 93% overall response rate and 74% complete response rate. So the data looks really good. Sorry, 94% and 73% complete response rate. So the data looks really good. It's significant, and it's a monotherapy with a time-limited course of therapy. It's only six cycles. When you're typically have patients on a BTK inhibitor, you're treating to progress. Patients can be on for a year or two years or even longer sometimes.
We think we have a really strong differentiator profile. We have now 43 patients efficacy evaluable. There will be an updated data cut at ASH, and with the full data set, we do plan to discuss the regulatory pathway with the FDA. We plan to have a breakthrough designation meeting with the FDA in the first half of next year, and we believe that there could be a potential path towards accelerated approval with this data set.
What is the size of the opportunity in MZL?
If you were to just multiply 3,000 to 4,000 patients times, on average, patients are getting around six cycles of ZYNLONTA times our price, the total addressable market opportunity is about $500 million. Meaning for every 10% share, it is an incremental $50 million opportunity for ZYNLONTA.
Great. Earlier you touched on a major restructuring and refinancing you conducted early in October. Walk us through how that changed the balance sheet and also the strategic flexibility of the company.
Yeah, we just announced a few weeks ago an equity financing, which was led by some of our current shareholders like Redmile, TCGX, and Nantahala Capital, but we also brought in very high-quality new investor in Bain Capital as well. That was also announced concurrently with reducing our debt principal from $120 million down to $50 million, and we were able to restructure the HealthCare Royalty agreement where the change of control provision that existed, which used to be $150 million-$200 million upon a change of control, went down to zero. So we, through all of this, were able to extend the cash runway to 2029 and significantly increase the strategic optionality for the company.
Okay. As you think about next steps around LOTIS-7, what role will Roche play in that, which is an existing partner as part of a trial collaboration?
Yeah, they've been a great partner. Up to this point, they've been providing study drug, but also a lot of, I would say, collaboration on the clinical design and regulatory side of things. Even I can tell you, when we submitted the briefing book for our Type B meeting coming up, we got a lot of great input from Roche. I think as things kind of come together, we'll be able to announce more, but what I would expect is that we'll continue to have good collaboration and good support from them as a partner on this study.
Okay, great. So as you look ahead, or if you were to summarize, what are the two or three key milestones over the next 12 or 18 months for-
Yeah, so with LOTIS-7, obviously we're going to have the presentation coming at ASH, publication, and then submission to NCCN guidelines, and hopefully inclusion in the first quarter of next year. In parallel, we have the regulatory guidance, the pathway where we have a Type B meeting coming up this quarter. We think over the course of that meeting and maybe some subsequent meetings, we should be able to get regulatory clarity. We hope to start that phase III study in the latter part of next year.
On the marginal zone lymphoma standpoint, we have, again, updated data getting presented in an oral presentation. We expect that we'll have a publication probably around mid-next year, and then get into compendia the second half of next year. In parallel, we're doing the regulatory pathway where we plan to submit for breakthrough designation in the first half of 2027, and then with aims to see if there's an accelerated approval pathway for marginal zone lymphoma.
Great. Well, thank you, Ameet.
Yeah, thank you, Michael. Appreciate it.
Thank you.
Thank you.